文献知网节
  • 记笔记

Novel Combined Response Endpoint Shows that Belimumab (Fully Human Monoclonal Antibody to B-Lymphocyte Stimulator [BLyS]) Improves or Stabilizes SLE Disease Activity in a Phase 2 Trial

Richard FurieDaniel WallaceJeffrey LisseWilliam StohlJoan MerrillMichelle PetriEllen GinzlerCynthia AranowArthur WeinsteinVibeke StrandVivian FernandezJohn ZhongWilliam FreimuthLBSL02 Study Group

North Shore-LIJ Health System,Lake Success,NYCedars-Sinai UCLA,Los Angeles,CAUniversity of Arizona Health Sciences Center,Tucson,AZUniversity of Southern California,Los Angeles,CA,Oklahoma Medical Research Foundation,Oldahoma City,OKJohns Hopkins University,Baltimore,MDSUNY Downstate,Brooklyn,NYColumbia University.New York,NYWashington Hospital Center,Washington,DCStanford Uni-versity,Palo Alto,CAHuman Genome Sciences,Rockville,MD,all authors from USA

摘要:<正>Purpose:To assess SLE-specific disease activity indices in the development of a novel combined responder index and its correlation with QOL and biomarker response. Methods:449 SLE subjects with screening SELENA SLEDAI(SS)scores≥4 enrolled in a 52 wk randomized, double-blind,placebo-controlled trial comparing belimumab
会议名称:

The 8th International Congress on SLE

会议时间:

2007-05

会议地点:

中国上海

  • 专辑:

    医药卫生科技

  • 专题:

    内分泌腺及全身性疾病

  • 分类号:

    R593.241

  • 手机阅读
    即刻使用手机阅读
    第一步

    扫描二维码下载

    "移动知网-全球学术快报"客户端

    第二步

    打开“全球学术快报”

    点击首页左上角的扫描图标

    第三步

    扫描二维码

    手机同步阅读本篇文献

  • CAJ下载
  • PDF下载

下载手机APP用APP扫此码同步阅读该篇文章

下载:13 页码:47-48 页数:2 大小:533k

引文网络
  • 参考文献
  • 引证文献
  • 共引文献
  • 同被引文献
  • 二级参考文献
  • 二级引证文献
  • 批量下载
相关推荐
  • 相似文献
  • 读者推荐
  • 相关基金文献
  • 相关法规
  • 关联作者
  • 相关视频